Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 0.76 |
| ▸ | ULK1 | O75385 | 1/20 | 0.72 |
| ▸ | KIF15 | Q9NS87 | 1/20 | 0.72 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395408 | 1.00 | RAF1 (0.76) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL1394705 | 0.89 | RAF1 (0.67) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL5084106 | 0.89 | RAF1 (0.67) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL7982366 | 0.88 | RAF1 (0.69) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL1394541 | 0.87 | JAK3 (0.66) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL1394544 | 0.87 | JAK3 (0.66) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL1394836 | 0.86 | RAF1 (1.00) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL12856488 | 0.86 | RAF1 (0.76) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL1394837 | 0.86 | RAF1 (1.00) | RAF1ULK1KIF15TLK2JAK3 | |
| SCHEMBL5773594 | 0.85 | RAF1 (0.67) | RAF1ULK1KIF15TLK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | RAF1 4132/4885ULK1 1261/4885KIF15 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.